GLORIA

GEOMAR Library Ocean Research Information Access

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    In: Liver International, Wiley, Vol. 38, No. 6 ( 2018-06), p. 1095-1101
    Kurzfassung: Chronic alcohol consumption and alcoholic liver disease ( ALD ) afflicts individuals with substantial morbidity and mortality with limited treatment options available. Hepatic inflammation, triggered by activated Kupffer cells, is a driving force in alcoholic liver disease. Interleukin 37 ( IL ‐37) exerts anti‐inflammatory effects in hepatic diseases, however, the impact of Interleukin 37 on alcoholic liver disease is unknown. In this study, we addressed the role of Interleukin 37 in alcoholic liver disease. Methods We utilized Interleukin 37 expressing transgenic mice and human recombinant Interleukin 37 in models of alcoholic liver disease. Interleukin 37 expression was measured in liver samples of 20 alcoholic steatohepatitis and 36 non‐alcoholic fatty liver disease patients. Results Interleukin 37 transgenic mice are not protected against hepatic injury and inflammation in alcoholic liver disease. Ethanol suppressed Interleukin 37 expression in transgenic mice. Alcoholic steatohepatitis ( ASH ) patients similarly exhibited reduced Interleukin 37 expression when compared to non‐alcoholic fatty liver disease ( NAFLD ) patients. Human recombinant Interleukin 37 ameliorated hepatic inflammation in a binge drinking model of alcoholic liver disease. Conclusion We provide evidence for an exogenous noxae that suppresses Interleukin 37 expression which limits its anti‐inflammatory effects in alcoholic liver disease.
    Materialart: Online-Ressource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2018
    ZDB Id: 2124684-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Wiley ; 2017
    In:  Liver International Vol. 37, No. 2 ( 2017-02), p. 299-306
    In: Liver International, Wiley, Vol. 37, No. 2 ( 2017-02), p. 299-306
    Kurzfassung: Obesity and its related co‐morbidities such as non‐alcoholic fatty liver disease ( NAFLD ) are increasing dramatically worldwide. The genetic variation in Patatin‐like phospholipase domain‐containing protein 3 ( PNPLA 3 ), which is also called adiponutrin ( ADPN ), in residue 148 (I148M, rs738409) has been associated with NAFLD . However, the regulation and function of PNPLA 3 in metabolic diseases remains unclear. Laparoscopic gastric banding ( LAGB ) of severely obese patients reduces body weight, liver and adipose tissue inflammation. In this study, we investigated whether weight loss induced by LAGB affected PNPLA 3 expression in hepatic and adipose tissue. Methods Liver and subcutaneous adipose tissue samples were collected from 28 severely obese patients before and 6 months after LAGB . PNPLA 3 expression was assessed by quantitative real‐time PCR . To understand whether inflammatory stimuli regulated PNPLA 3 expression, we studied the effect of tumour necrosis factor alpha ( TNF α) and lipopolysaccharide ( LPS ) on PNPLA 3 expression in human adipocytes and hepatocytes. Results PNPLA 3 was strongly expressed in the liver and clearly detectable in subcutaneous adipose tissue of obese patients. Weight loss induced by LAGB of severely obese patients led to significantly increased adipose, but not hepatic, tissue expression of PNPLA 3 . Subcutaneous PNPLA 3 expression negatively correlated with body‐mass‐index, fasting glucose and fasting insulin. TNF α potently suppressed PNPLA 3 expression in adipocytes but not hepatocytes. Conclusions Weight loss induced by LAGB restored adipose tissue PNPLA 3 expression which is suppressed by TNF α. Further studies will be required to determine the functional impact of PNPLA 3 and its related genetic variation on adipose tissue inflammation and NAFLD .
    Materialart: Online-Ressource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2017
    ZDB Id: 2124684-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    In: Liver International, Wiley, Vol. 40, No. 7 ( 2020-07), p. 1610-1619
    Kurzfassung: Alcohol‐related liver disease (ALD) comprises different liver disorders which impose a health care issue. ALD and particularly alcoholic steatohepatitis, an acute inflammatory condition, cause a substantial morbidity and mortality as effective treatment options remain elusive. Inflammation in ALD is fuelled by macrophages (Kupffer cells [KCs]) which are activated by intestinal pathogen associated molecular patterns, eg lipopolysaccharide (LPS), disseminated beyond a defective intestinal barrier. We hypothesized that the immunomodulator dimethyl‐fumarate (DMF), which is approved for the treatment of human inflammatory conditions such as multiple sclerosis or psoriasis, ameliorates the course of experimental ALD. Methods Dimethyl‐fumarate or vehicle was orally administered to wild‐type mice receiving a Lieber‐DeCarli diet containing 5% ethanol for 15 days. Liver injury, steatosis and inflammation were evaluated by histology, biochemical‐ and immunoassays. Moreover, we investigated a direct immunosuppressive effect of DMF on KCs and explored a potential impact on ethanol‐induced intestinal barrier disruption. Results Dimethyl‐fumarate protected against ethanol‐induced hepatic injury, steatosis and inflammation in mice. Specifically, we observed reduced hepatic triglyceride and ALT accumulation, reduced hepatic expression of inflammatory cytokines ( Tnf‐α, Il‐1β, Cxcl1 ) and reduced abundance of neutrophils and macrophages in ethanol‐fed and DMF‐treated mice when compared to vehicle. DMF protected against ethanol‐induced barrier disruption and abrogated systemic LPS concentration. In addition, DMF abolished LPS‐induced cytokine responses of KCs. Conclusions Dimethyl‐fumarate counteracts ethanol‐induced barrier dysfunction, suppresses inflammatory responses of KCs and ameliorates hepatic inflammation and steatosis, hallmarks of experimental ALD. Our data indicates that DMF treatment might be beneficial in human ALD and respective clinical trials are eagerly awaited.
    Materialart: Online-Ressource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    Sprache: Englisch
    Verlag: Wiley
    Publikationsdatum: 2020
    ZDB Id: 2124684-1
    Standort Signatur Einschränkungen Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...